15/11/2024  17:32:14 Diferencia -26.90 Volumen Bid17:32:14 Ask17:32:14 Capitalización de mecado Dividendo A. P/E Ratio
437.35EUR -5.79% 25
Volumen de negocios: 11,368.15
-Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 113.92 mil millonesEUR - -

Descripción de negocio

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
 

Consejo de gestión & Consejo de supervisión

CEO
Reshma Kewalramani, M.D.
Consejo de gestión
Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D.
Consejo de supervisión
Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay
 

Datos de la empresa

Nombre: Vertex Pharmaceuticals Inc.
Dirección: 50 Northern Avenue,Boston, Massachusetts 02210, USA
Teléfono: +1-617-961-7163
Fax: -
E-mail: Investorinfo@VRTX.com
Internet: www.vrtx.com/
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: 82.70%
Fecha de OPI: 24/07/1991

Relación con inversores

Nombre: Susie Lisa
IR teléfono: +1-617-341-6108
IR-fax: -
IR e-mail: investorinfo@vrtx.com

Accionistas mayoritarios

Otros
 
53.31%
Vanguard Group
 
8.63%
BlackRock Inc.
 
8.48%
Capital World Investors
 
8.45%
FMR LLC.
 
5.03%
State Street Corporation
 
4.68%
ALLIANCEBERNSTEIN L P
 
2.73%
PRICE T ROWE ASSOCIATES INC MD
 
2.28%
GEODE CAPITAL MANAGEMENT LLC
 
2.20%
Otros
 
4.21%